Natera (NTRA) said Wednesday its Prospera Lung test has obtained coverage from the Centers for Medicare & Medicaid Services for single lung transplant recipients in the surveillance setting.
The company said the Prospera Lung test first obtained Medicare coverage for double-lung transplant patients in 2023.
Price: 167.98, Change: -0.34, Percent Change: -0.20
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments